Outsourcing Outlook: Will CROs find opportunity in a Reinvigorated European R&D Sector?

Author(s)Jim Miller, Janet Lowenbach

by Jim Miller and Janet Lowenbach, PharmSource Information Services The EU must harness market forces that reward innovation and competitiveness to combat its current R&D drain.

To view a PDF of this article from the BioPharm International archives, click this link

Articles in this issue

almost 23 years ago

Article

Inside Washington: Major Changes Ahead for FDA

almost 23 years ago

Article

Bioinformatics Databases ? Questions of Copyright

almost 23 years ago

Article

European Editor's Report ? An Industry Comes of Age

almost 23 years ago

Article

Guest Editorial: Back to the Beginning

almost 23 years ago

Article

Employing Near-Infrared Spectroscopic Methods of Analysis for Fermentation Monitoring and Control: Part 1, Method Development

almost 23 years ago

Article

You Have Failed . . . A Case Study in Warning Letter Remediation

almost 23 years ago

Article

Survival Guide to FDA Inspections: Part 3, Responding to Observations

almost 23 years ago

Article

Analytical Advances: The Protein ID Autobahn ? Automated Nanoelectrospray Mass Spectrometry

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!

Outsourcing Outlook: Will CROs find opportunity in a Reinvigorated European R&D Sector?

Articles in this issue

Newsletter

Trending on BioPharm International

How India’s Biotech Ecosystem Is Shifting Toward Innovation and Global Partnerships

RNAnalytics Goes Beyond Nanoparticle Analysis at CPHI Frankfurt